(Q43967348)

28 November 2017

title

Safety and efficacy of KOGENATE Bayer in previously untreated patients (PUPs) and minimally treated patients (MTPs). (English)

1 reference

antihemophilic factor, human recombinant

28 November 2017

main subject

1 reference

P L F Giangrande

1

1 reference

28 November 2017

KOGENATE Bayer Study Group

series ordinal

2

1 reference

28 November 2017

publication date

1 March 2002

1 reference

28 November 2017

1 reference

28 November 2017

volume

8 Suppl 2

1 reference

28 November 2017

page(s)

19-22

1 reference

Efficacy of a sucrose-formulated recombinant factor VIII used for 22 surgical procedures in patients with severe haemophilia A.

28 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1351-8216.2001.00133.X

Factor VIII gene inversions in severe hemophilia a patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1351-8216.2001.00133.X

Emerging issues in blood safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1351-8216.2001.00133.X

Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1351-8216.2001.00133.X

Human recombinant DNA-derived antihaemophilic factor (factor VIII) in the treatment of haemophilia A: conclusions of a 5-year study of home therapy. The KOGENATE Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1351-8216.2001.00133.X

Incidence of inhibitors in haemophilia A patients--a review of recent studies of recombinant and plasma-derived factor VIII concentrates

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1351-8216.2001.00133.X

10.1046/J.1351-8216.2001.00133.X

21 January 2018

Identifiers

DOI

1 reference

28 November 2017

1 reference